Physician profile
Khaled Fareed
NPI 1487671368
$13,588.40
in general payments reported to CMS, 2019-2025
35 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,473 · 2021: $1,124 · 2022: $7,622 · 2023: $816 · 2024: $291 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.22 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,199.79 | 2019-2022 | |
| Teleflex LLC | $3,237.57 | 2021-2025 | Urolift, Barrigel |
| C. R. Bard, INC. & Subsidiaries | $611.67 | 2021-2022 | |
| Astellas Pharma US INC | $436.09 | 2021-2024 | Xtandi |
| Medtronic, INC. | $382.91 | 2022-2023 | Interstim |
| Sumitomo Pharma America, INC. | $268.15 | 2023-2025 | Orgovyx, Gemtesa |
| Olympus America INC. | $250.27 | 2022 | |
| Boston Scientific Corporation | $240.68 | 2019 | |
| Neotract INC. | $240.67 | 2019 | |
| Myovant Sciences INC. | $178.75 | 2021-2022 | |
| Janssen Biotech, INC. | $161.58 | 2022-2025 | Erleada |
| Halozyme INC | $155.91 | 2023 | |
| Incyte Corporation | $124.99 | 2021 | |
| Progenics Pharmaceuticals, INC. | $106.13 | 2022 | |
| Endo Pharmaceuticals INC. | $104.82 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $97.40 | 2022-2024 | Illuccix |
| Profound Medical Corp. | $86.00 | 2023 | Tulsa-Pro |
| Coloplast Corp | $78.26 | 2021-2025 | |
| Abbvie INC. | $70.94 | 2022-2023 | |
| Accord Healthcare, INC. | $65.19 | 2022-2024 | |
| Antares Pharma, INC. | $59.67 | 2022 | |
| Myriad Genetic Laboratories, INC. | $55.68 | 2022 | |
| Alnylam Pharmaceuticals INC. | $44.98 | 2021 | |
| Immunitybio, INC. | $40.78 | 2025 | |
| Abc Home Medical Supply, INC. | $40.44 | 2022 | |
| Foundation Medicine, INC. | $36.32 | 2022 | |
| Srs Medical Systems, INC. | $32.40 | 2021 | |
| Procept Biorobotics Corporation | $28.34 | 2022 | |
| Hollister Incorporated | $26.79 | 2021 | |
| Angiodynamics, INC. | $24.95 | 2023 | Nanoknife |
| Abbott Laboratories | $23.58 | 2023 | Proclaim |
| Pfizer INC. | $22.45 | 2025 | |
| Urovant Sciences INC | $20.86 | 2022 | |
| Ambu INC. | $16.81 | 2021 | |
| Biotissue Holdings INC. | $16.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Fareed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.